|
1
|
Guo Z and Sadler PJ: Metals in medicine.
Angew Chem Int Edit. 38:1512–1531. 1999. View Article : Google Scholar
|
|
2
|
Schmitt SM, Frezza M and Dou QP: New
applications of old metal-binding drugs in the treatment of human
cancer. Front Biosci (Schol Ed.). 4:375–391. 2012.PubMed/NCBI
|
|
3
|
Verani CN: Metal complexes as inhibitors
of the 26S proteasome in tumor cells. J Inorg Biochem. 106:59–67.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen D, Milacic V, Frezza M and Dou QP:
Metal Complexes, their cellular targets and potential for cancer
therapy. Curr Pharm Des. 15:777–791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang CX and Lippard SJ: New metal
complexes as potential therapeutics. Curr Opin Chem Biol.
7:481–499. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Skrott Z and Cvek B:
Diethyldithiocarbamate complex with copper: The mechanism of action
in cancer cells. Mini Rev Med Chem. 12:1184–1192. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berners-Price SJ and Filipovska A: Gold
compounds as therapeutic agents for human diseases. Metallomics.
3:863–873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fregona D, Giovagnini L, Ronconi L,
Marzano C, Trevisan A, Sitran S, Biondi B and Bordin F: Pt(II) and
Pd(II) derivatives of ter-butylsarcosinedithiocarbamate. Synthesis,
chemical and biological characterization and in vitro
nephrotoxicity. J Inorg Biochem. 93:181–189. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen D, Frezza M, Shakya R, Cui QC,
Milacic V, Verani CN and Dou QP: Inhibition of the proteasome
activity by gallium(III) complexes contributes to their anti
prostate tumor effects. Cancer Res. 67:9258–9265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen D, Cui QC, Yang H and Dou QP:
Disulfiram, a clinically used anti-alcoholism drug and
copper-binding agent, induces apoptotic cell death in breast cancer
cultures and xenografts via inhibition of the proteasome activity.
Cancer Res. 66:10425–10433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen D, Cui QC, Yang H, Barrea RA, Sarkar
FH, Sheng S, Yan B, Reddy GP and Dou QP: Clioquinol, a therapeutic
agent for Alzheimer's disease, has proteasome-inhibitory, androgen
receptor-suppressing, apoptosis-inducing, and antitumor activities
in human prostate cancer cells and xenografts. Cancer Res.
67:1636–1644. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhai S, Yang L, Cui QC, Sun Y, Dou QP and
Yan B: Tumor cellular proteasome inhibition and growth suppression
by 8-hydroxyquinoline and clioquinol requires their capabilities to
bind copper and transport copper into cells. J Biol Inorg Chem.
15:259–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang Y, Kitagaki J, Wang H, Hou DX and
Perantoni AO: Targeting the ubiquitin-proteasome system for cancer
therapy. Cancer Sci. 100:24–28. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ciehanover A, Hod Y and Hershko A: A
heat-stable polypeptide component of an ATP-dependent proteolytic
system from reticulocytes. Biochem Biophys Res Commun.
81:1100–1105. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hershko A, Ciechanover A, Heller H, Haas
AL and Rose IA: Proposed role of ATP in protein breakdown:
Conjugation of protein with multiple chains of the polypeptide of
ATP-dependent proteolysis. Proc Natl Acad Sci USA. 77:1783–1786.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nalepa G, Rolfe M and Harper JW: Drug
discovery in the ubiquitin-proteasome system. Nat. Rev Drug Discov.
5:596–613. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adams J: The proteasome: A suitable
antineoplastic target. Nat Rev Cancer. 4:349–60. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frezza M, Schmitt S and Dou QP: Targeting
the ubiquitin-proteasome pathway: An emerging concept in cancer
therapy. Curr Top Med Chem. 11:2888–2905. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wójcik C and DeMartino GN: Intracellular
localization of proteasomes. Int J Biochem Cell Biol. 35:579–2589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nandi D, Tahiliani P, Kumar A and Chandu
D: The ubiquitin-proteasome system. J Biosci. 31:137–155. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Groll M, Heinemeyer W, Jäger S, Ullrich T,
Bochtler M, Wolf DH and Huber R: The catalytic sites of 20S
proteasomes and their role in subunit maturation: A mutational and
crystallographic study. Proc Natl Acad Sci USA. 96:10976–10983.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Via L Dalla, Nardon C and Fregona D:
Targeting the ubiquitin-proteasome pathway with inorganic compounds
to fight cancer: A challenge for the future. Future Med Chem.
4:525–543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
An B, Goldfarb RH, Siman R and Dou QP:
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective
function and selectively accumulate the cyclin-dependent kinase
inhibitor p27 and induce apoptosis in transformed, but not normal,
human fibroblasts. Cell Death Differ. 5:1062–1075. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rajkumar SV, Richardson PG, Hideshima T
and Anderson KC: Proteasome inhibition as a novel therapeutic
target in human cancer. J Clin Oncol. 23:630–639. 2005.PubMed/NCBI
|
|
25
|
Orlowski RZ and Kuhn DJ: Proteasome
inhibitors in cancer therapy: Lessons from the first decade. Clin
Cancer Res. 14:1649–1657. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kane RC, Bross PF, Farrell AT and Pazdur
R: Velcade: U.S. FDA approval for the treatment of multiple myeloma
progressing on prior therapy. Oncologist. 8:508–513. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Potts BC, Albitar MX, Anderson KC,
Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC
Jr, Fenical W, et al: Marizomib, a proteasome inhibitor for all
seasons: Preclinical profile and a framework for clinical trials.
Curr Cancer Drug Tar. 11:254–284. 2011. View Article : Google Scholar
|
|
28
|
Kane RC, Dagher R, Farrell A, Ko CW,
Sridhara R, Justice R and Pazdur R: Bortezomib for the treatment of
mantle cell lymphoma. Clin Cancer Res. 13:5291–5294. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kuhn DJ, Orlowski RZ and Bjorklund C:
Second generation proteasome inhibitors: Carfilzomib and
immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug
Targets. 11:285–295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kuhn DJ, Chen Q, Voorhees PM, Strader JS,
Shenk KD, Sun CM, Demo SD, Bennett MK, Leeuwen FW, Chanan-Khan AA
and Orlowski RZ: Potent activity of carfilzomib, a novel,
irreversible inhibitor of the ubiquitin-proteasome pathway, against
preclinical models of multiple myeloma. Blood. 110:3281–3290. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kupperman E, Lee EC, Cao Y, Bannerman B,
Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, et al:
Evaluation of the proteasome inhibitor MLN9708 in preclinical
models of human cancer. Cancer Res. 70:1970–1980. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee EC, Fitzgerald M, Bannerman B, Donelan
J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, et
al: Antitumor activity of the investigational proteasome inhibitor
MLN9708 in mouse models of B-cell and plasma cell malignancies.
Clin Cancer Res. 17:7313–7323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sanchez E, Li M, Steinberg JA, Wang C,
Shen J, Bonavida B, Li ZW, Chen H and Berenson JR: The proteasome
inhibitor CEP-18770 enhances the anti-myeloma activity of
bortezomib and melphalan. Br J Haematol. 148:569–581. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Labbe S and Thiele DJ: Pipes and wiring:
The regulation of copper uptake and distribution in yeast. Trends
Microbiol. 7:500–505. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tapiero H, Townsend DM and Tew KD: Trace
elements in human physiology and pathology. Copper. Biomed
Pharmacother. 57:386–398. 2003. View Article : Google Scholar
|
|
36
|
Kuo HW, Chen SF, Wu CC, Chen DR and Lee
JH: Serum and tissue trace elements in patients with breast cancer
in Taiwan. Biol Trace Elem Res. 89:1–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nayak SB, Bhat VR, Upadhyay D and Udupa
SL: Copper and ceruloplasmin status in serum of prostate and colon
cancer patients. Indian J Physiol Pharmacol. 47:108–110.
2003.PubMed/NCBI
|
|
38
|
Diez M, Arroyo M, Cerdàn FJ, Muñoz M,
Martin MA and Balibrea JL: Serum and tissue trace metal levels in
lung cancer. Oncology. 46:230–234. 1989.PubMed/NCBI
|
|
39
|
Turecký L, Kalina P, Uhlíková E, Námerová
S and Krizko J: Serum ceruloplasmin and copper levels in patients
with primary brain tumors. Klin Wochenschr. 62:187–189. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Finney L, Vogt S, Fukai T and Glesne D:
Copper and angiogenesis: Unravelling a relationship key to cancer
progression. Clin Exp Pharmacol Physiol. 36:88–94. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fox SB, Gasparini G and Harris AL:
Angiogenesis: Pathological, prognostic, and growth-factor pathways
and their link to trial design and anticancer drugs. Lancet Oncol.
2:278–289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rau KM, Huang CC, Chiu TJ, Chen YY, Lu CC,
Liu CT, Pei SN and Wei YC: Neovascularization evaluated by CD105
correlates well with prognostic factors in breast cancers. Exp Ther
Med. 4:231–236. 2012.PubMed/NCBI
|
|
43
|
Daniel KG, Harbach RH, Guida WC and Dou
QP: Copper storage diseases: Menkes, Wilson's, and cancer. Front
Biosci. 9:2652–2662. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Daniel KG, Gupta P, Harbach RH, Guida WC
and Dou QP: Organic copper complexes as a new class of proteasome
inhibitors and apoptosis inducers in human cancer cells. Biochem
Pharmacol. 67:1139–1151. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Daniel KG, Chen D, Orlu S, Cui QC, Miller
FR and Dou QP: Clioquinol and pyrrolidine dithiocarbamate complex
with copper to form proteasome inhibitors and apoptosis inducers in
human breast cancer cells. Breast Cancer Res. 7:R897–R908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Daniel KG, Chen D, Yan B and Dou QP:
Copper-binding compounds as proteasome inhibitors and apoptosis
inducers in human cancer. Front Biosci. 12:135–144. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Barrea RA, Chen D, Irving TC and Dou QP:
Synchrotron X-ray imaging reveals a correlation of tumor copper
speciation with clioquinol's anticancer activity. J Cell Biochem.
108:96–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ritchie CW, Bush AI and Masters CL:
Metal-protein attenuating compounds and Alzheimer's disease. Expert
Opin Investig Drugs. 13:1585–1592. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ritchie CW, Bush AI, Mackinnon A,
Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX,
Tammer A, et al: Metal-protein attenuation with
iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid
deposition and toxicity in Alzheimer disease: A pilot phase 2
clinical trial. Arch Neurol. 60:1685–1691. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Barcia E, Salama A, Fernández-Carballido A
and Negro S: Protective effects of clioquinol on human
neuronal-like cells: A new formulation of clioquinol-loaded PLGA
microspheres for Alzheimer's disease. J Drug Target. 19:637–646.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mao F, Yan J, Li J, Jia X, Miao H, Sun Y,
Huang L and Li X: New multi-target-directed small molecules against
Alzheimer's disease: A combination of resveratrol and clioquinol.
Org Biomol Chem. 12:5936–5944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen D, Peng FY, Cui QC, Daniel KG, Orlu
S, Liu JG and Dou QP: Inhibition of prostate cancer cellular
proteasome activity by a pyrrolidine dithiocarbamate-copper complex
is associated with suppression of proliferation and induction of
apoptosis. Front Biosci. 10:2932–2939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yu Z, Wang F, Milacic V, Li X, Cui QC,
Zhang B, Yan B and Dou QP: Evaluation of copper-dependent
proteasome-inhibitory and apoptosis-inducing activities of novel
pyrrolidine dithiocarbamate analogues. Int J Mol Med. 20:919–925.
2007.PubMed/NCBI
|
|
54
|
Wang F, Zhai S, Liu X, Li L, Wu S, Dou QP
and Yan B: A novel dithiocarbamate analogue with potentially
decreased ALDH inhibition has copper-dependent
proteasome-inhibitory and apoptosis-inducing activity in human
breast cancer cells. Cancer Lett. 300:87–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Meyer RE: Prospects for a rational
pharmacotherapy of alcoholism. J Clin Psychiatry. 50:403–412.
1989.PubMed/NCBI
|
|
56
|
Reisinger EC, Kern P, Ernst M, Bock P,
Flad HD and Dietrich M: Inhibition of HIV progression by
dithiocarb. German DTC Study Group. Lancet. 335:679–682. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hersh EM, Brewton G, Abrams D, Bartlett J,
Galpin J, Gill P, Gorter R, Gottlieb M, Jonikas JJ and Landesman S:
Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with
symptomatic HIV infection and AIDS. A randomized, double-blind,
placebo-controlled, multicenter study. JAMA. 265:1538–1544. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pang H, Chen D, Cui QC and Dou QP: Sodium
diethyldithiocarbamate, an AIDS progression inhibitor and a
copper-binding compound, has proteasome-inhibitory and
apoptosis-inducing activities in cancer cells. Int J Mol Med.
19:809–816. 2007.PubMed/NCBI
|
|
59
|
Han J, Li L, Yue X, Chang J, Shi W and Hua
Y: A binuclear complex constituted by diethyldithiocarbamate and
copper(I) functions as a proteasome activity inhibitor in
pancreatic cancer cultures and xenografts. Toxicol Appl Pharmacol.
273:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cerchiaro G, Aquilano K, Filomeni G,
Rotilio G, Ciriolo MR and Ferreira AM: Isatin-Schiff base
copper(II) complexes and their influence on cellular viability. J
Inorg Biochem. 99:1433–1440. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Adsule S, Barve V, Chen D, Ahmed F, Dou
QP, Padhye S and Sarkar FH: Novel Schiff base copper complexes of
quinoline-2 carboxyaldehyde as proteasome inhibitors in human
prostate cancer cells. J Med Chem. 49:7242–7246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Xiao Y, Bi C, Fan Y, Cui C, Zhang X and
Dou QP: L-glutamine Schiff base copper complex as a proteasome
inhibitor and an apoptosis inducer in human cancer cells. Int J
Oncol. 33:1073–1079. 2008.PubMed/NCBI
|
|
63
|
Zhong X, Yi J, Sun J, Wei HL, Liu WS and
Yu KB: Synthesis and crystal structure of some transition metal
complexes with a novel bis-Schiff base ligand and their antitumor
activities. Eur J Med Chem. 41:1090–1092. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Creaven BS, Devereux M, Karcz D, Kellett
A, McCann M, Noble A and Walsh M: Copper(II) complexes of
coumarin-derived Schiff bases and their anti-Candida activity. J
Inorg Biochem. 103:1196–1203. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Creaven BS, Czeglédi E, Devereux M, Enyedy
ÉA, Foltyn-Arfa Kia A, Karcz D, Kellett A, McClean S, Nagy NV,
Noble A, et al: Biological activity and coordination modes of
copper(II) complexes of Schiff base-derived coumarin ligands.
Dalton Trans. 39:10854–10865. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Duff B, Thangella VR, Creaven BS, Walsh M
and Egan DA: Anti-cancer activity and mutagenic potential of novel
copper(II) quinolinone Schiff base complexes in hepatocarcinoma
cells. Eur J Pharmacol. 689:45–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang X, Bi CF, Fan Y, Cui Q, Chen D, Xiao
Y and Dou QP: Induction of tumor cell apoptosis by taurine Schiff
base copper complex is associated with the inhibition of
proteasomal activity. Int J Mol Med. 22:677–682. 2008.PubMed/NCBI
|
|
68
|
Zuo J, Bi C, Fan Y, Buac D, Nardon C,
Daniel KG and Dou QP: Cellular and computational studies of
proteasome inhibition and apoptosis induction in human cancer cells
by amino acid Schiff base-copper complexes. J Inorg Biochem.
118:83–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang Z, Bi CF, Fan YH, Zhang N, Deshmukh
R, Yan X, Lv X, Zhang P, Zhang X and Dou QP: L-Ornithine Schiff
base-copper and -cadmium complexes as new proteasome inhibitors and
apoptosis inducers in human cancer cells. J Biol Inorg Chem.
20:109–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hindo SS, Frezza M, Tomco D, Heeg MJ,
Hryhorczuk L, McGarvey BR, Dou QP and Verani CN: Metals in
anticancer therapy: Copper(II) complexes as inhibitors of the 20S
proteasome. Eur J Med Chem. 44:4353–4361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhang Z, Bi C, Schmitt SM, Fan Y, Dong L,
Zuo J and Dou QP: 1,10-Phenanthroline promotes copper complexes
into tumor cells and induces apoptosis by inhibiting the proteasome
activity. J Biol Inorg Chem. 17:1257–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang S and Zhou J: Ternary copper(II)
complex of 1,10-phenanthroline and glycine: Crystal structure and
interaction with DNA. J Coord Chem. 61:2488–2498. 2008. View Article : Google Scholar
|
|
73
|
Seng HL, Wang WS, Kong SM, Ong HK Alan,
Win YF, Abd Rahman RN Raja, Chikira M, Leong WK, Ahmad M, Khoo AS
and Ng CH: Biological and cytoselective anticancer properties of
copper(II)-polypyridyl complexes modulated by auxiliary methylated
glycine ligand. Biometals. 125:1061–1681. 2012.
|
|
74
|
Ng CH, Kong SM, Tiong YL, Maah MJ, Sukram
N, Ahmade M and Khoo AB: Selective anticancer copper(II)-mixed
ligand complexes: Targeting of ROS and proteasomes. Metallomics.
6:892–906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dallavalle F, Gaccioli F, Franchi-Gazzola
R, Lanfranchi M, Marchiò L, Pellinghelli MA and Tegoni M:
Synthesis, molecular structure, solution equilibrium, and
antiproliferative activity of thioxotriazoline and thioxotriazole
complexes of copper II and palladium II. J Inorg Biochem.
92:95–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Tardito S, Isella C, Medico E, Marchiò L,
Bevilacqua E, Hatzoglou M, Bussolati O and Franchi-Gazzola R: The
thioxotriazole copper(II) complex A0 induces endoplasmic reticulum
stress and paraptotic death in human cancer cells. J Biol Chem.
284:24306–24319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Gandin V, Pellei M, Tisato F, Porchia M,
Santini C and Marzano C: A novel copper complex induces paraptosis
in colon cancer cells via the activation of ER stress signaling. J
Cell Mol Med. 16:142–151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Marzano C, Gandin V, Pellei M, Colavito D,
Papini G, Lobbia GG, Del Giudice E, Porchia M, Tisato F and Santini
C: In vitro antitumor activity of the water soluble copper(I)
complexes bearing the tris(hydroxymethyl)phosphine ligand. J Med
Chem. 51:798–808. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Bortolozzi R, Viola G, Porcù E, Consolaro
F, Marzano C, Pellei M, Gandin V and Basso G: A novel copper(I)
complex induces ER-stress-mediated apoptosis and sensitizes B-acute
lymphoblastic leukemia cells to chemotherapeutic agents.
Oncotarget. 5:5978–5991. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Liu N, Liu C, Li X, Liao S, Song W, Yang
C, Zhao C, Huang H, Guan L, Zhang P, et al: A novel proteasome
inhibitor suppresses tumor growth via targeting both 19S proteasome
deubiquitinases and 20S proteolytic peptidases. Sci Rep.
4:52402014.PubMed/NCBI
|
|
81
|
Gourley M and Williamson JS: Angiogenesis:
New targets for the development of anticancer chemotherapies. Curr
Pharm Des. 6:417–439. 2000. View Article : Google Scholar : PubMed/NCBI
|
